Obinutuzumab Induced Decreases of PLA2R Antibodies in Membranous Nephropathy: a Pilot Study
Obinutuzumab Induced Decreases of PLA2Rab in MN: a Pilot Study
Radboud University Medical Center
20 participants
Oct 1, 2025
INTERVENTIONAL
Conditions
Summary
Objective: To assess the disappearance rate (half-life) of anti-PLA2R antibodies in high-risk primary membranous nephropathy (pMN) patients treated with obinutuzumab (OBI), and to evaluate immunological and clinical remission, adverse events, and quality of life. Design: Open-label, single-center, prospective pilot intervention study conducted at Radboud University Medical Center. Population: 20 adult patients with high-risk PMN, defined by proteinuria ≥3.5 g/24h despite 6 months of supportive treatment with ACE inhibitors or ARBs. Intervention: OBI 1000 mg on days 1 and 15, with two additional infusions after 6 months if anti-PLA2R antibody levels remain positive and proteinuria exceeds 2 g/24h. Follow-up: Patients were monitored at baseline, and at weeks 1, 2, 4, 8, 12, 24, 37, and 52.
Eligibility
Inclusion Criteria9
- Age ≥ 18 years.
- Diagnosis of PMN, confirmed by:
- Kidney biopsy or
- Positive serum PLA2Rab test either by IFT and/or ELISA)
- Serum PLA2Rab titer > 80 RU/ml
- Proteinuria ≥ 3.5 g/24h despite supportive treatment for at least 6 months with a maximally tolerated and stable dose of ACE-i or ARB.
- Serum albumin < 30 g/l measured by BCP assay.
- eGFR ≥ 30 ml/min/1.73m2.
- Treatment with immunosuppression is warranted, as determined by the treating physician.
Exclusion Criteria14
- Secondary MN (e.g., hepatitis B or C infection, human immunodeficiency virus infection, active infection, systemic lupus erythematosus, sarcoidosis, IgG4-related, drug-induced, malignancy).
- RTX within 12 months prior to inclusion.
- CNI within 2 months prior to inclusion.
- Treatment with other immunosuppressive drugs within 6 months prior to inclusion.
- Proteinuria must not have decreased by > 50% over 6 months whilst taking ACEi/ARB.
- Life-threatening nephrotic syndrome resistant to treatment.
- > 20% increase in serum creatinine not otherwise explained during antiproteinuric supportive treatment.
- Pregnancy or breastfeeding. Women of childbearing age and male patients with female partners of childbearing potential not willing to use contraception throughout the study and for at least 6 months after the last dose of obinutuzumab.
- Suspected or known hypersensitivity, allergy, and/or immunogenic reaction history to monoclonal antibodies, corticosteroid, cyclophosphamide, any of their ingredients, and any other drugs from these same pharmacotherapeutic groups.
- Known active infection of any kind or recent major episode of infection.
- Any disorder or condition which might pose an unacceptable risk to patient's safety and well-being that might interfere with completion of the study.
- Inability to understand or comply with the requirements of the study.
- Incapable of recognizing the nature, significance, and scope of the clinical trial or giving consent even with a legal representative.
- Use of an investigational agent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
All participants will receive obinutuzumab 1000 mg on day 1 and 15, with two additional infusions after 6 months if the anti-PLA2R antibody IFT assay is still positive with proteinuria \> 2 gram/24 hours and stable kidney function.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07163611